Page 219 - Drug Class Review
P. 219
Drug Effectiveness Review Project
Drugs Authors: Tariot et al. 60 Forest Research Institute, a division of Forest Laboratories To compare the efficacy and safety of MEM in patients with moderate to severe AD already receiving Setting: Multi-center (37 sites) placebo memantine N/A 20mg/d titrated in 5 mg/d doses 24 weeks 24 weeks 201 203 Probable AD by NINCDS; MMSE score of 5 – 14; > 50 yrs old; recent (within 12 months) MRI or CT scan consistent with probable AD; ongoing ChE inhibitor with DON for more than 6 months before entrance into trial and as stable dose (5-10 mg/d) for at least 3 months; rel
Alzheimer Year: 2004 Country: US DON treatment Study design: RCT Sample size: 404
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
